Building Biomanufacturing Capacity: GCC's Strategic Investment in the Biologics Sector to Localize Production
nations are strategically prioritizing the development of local biologics manufacturing capabilities, aiming to reduce their dependence on imported high-value treatments like monoclonal antibodies and vaccines. This initiative is a core component of national economic diversification plans, ensuring supply security for complex chronic and rare diseases.
Significant public-private investment is targeting the establishment of specialized biotech hubs to accelerate the local production of biosimilars, which are vital for cost control within state-funded healthcare systems. The push for localized research and advanced therapies is positioning the GCC as a future regional hub for biopharma innovation.
2 Views